Currently, five RCTs are ongoing to ascertain the therapeutic potential of anti-IL-6 antibody in COVID-19 (NCT04381052, NCT04348500, NCT04494724, NCT04343989, NCT04343989). This evidence concerns the gene IL6 and COVID-19.